<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>春风健康 | wechat-feeds</title><link>http://MzI4NTI5NDU4OA.favicon.privacyhide.com/favicon.ico</link><description>中国临床研究服务领域的交流平台</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 10 Jun 2021 19:17:56 +0800</pubDate><image><url>http://MzI4NTI5NDU4OA.favicon.privacyhide.com/favicon.ico</url><title>春风健康 | wechat-feeds</title><link>http://MzI4NTI5NDU4OA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>CTLA-4+PD-1！信达双免疫疗法招募晚期肝细胞癌患者</title><link>https://mp.weixin.qq.com/s/CffcFPn1XdF5zD9w1bECzg</link><description></description><content:encoded><![CDATA[CTLA-4+PD-1！信达双免疫疗法招募晚期肝细胞癌患者]]></content:encoded><pubDate>Thu, 10 Jun 2021 17:58:29 +0800</pubDate></item><item><title>首款胆管癌靶向药，ASCO最新疗效数据令人惊喜！</title><link>https://mp.weixin.qq.com/s/-RG1oG7bDQN7bKHamtLYQw</link><description></description><content:encoded><![CDATA[首款胆管癌靶向药，ASCO最新疗效数据令人惊喜！]]></content:encoded><pubDate>Wed, 09 Jun 2021 17:08:09 +0800</pubDate></item><item><title>患者福音！罗氏T药招募三阴乳腺癌患者</title><link>https://mp.weixin.qq.com/s/Apm_qytqX82Vb3FMvKGY6A</link><description></description><content:encoded><![CDATA[患者福音！罗氏T药招募三阴乳腺癌患者]]></content:encoded><pubDate>Tue, 08 Jun 2021 17:59:19 +0800</pubDate></item><item><title>漫话“懒癌”，这种癌虽然慢，但也要重视起来</title><link>https://mp.weixin.qq.com/s/Fh7rln-JTLmugDqvkMgpzA</link><description></description><content:encoded><![CDATA[漫话“懒癌”，这种癌虽然慢，但也要重视起来]]></content:encoded><pubDate>Mon, 07 Jun 2021 13:43:36 +0800</pubDate></item><item><title>【肺癌招募】神州细胞抗VEGF抗体招募非小细胞肺癌患者</title><link>https://mp.weixin.qq.com/s/AhlU1QNLZ0s3JKEUAqUxPA</link><description></description><content:encoded><![CDATA[【肺癌招募】神州细胞抗VEGF抗体招募非小细胞肺癌患者]]></content:encoded><pubDate>Sun, 06 Jun 2021 17:08:58 +0800</pubDate></item><item><title>【胃癌招募】贝伐珠单抗类似药联合紫杉醇招募晚期胃癌患者</title><link>https://mp.weixin.qq.com/s/0c3GWja-jRCc_ElCr6DpPA</link><description></description><content:encoded><![CDATA[【胃癌招募】贝伐珠单抗类似药联合紫杉醇招募晚期胃癌患者]]></content:encoded><pubDate>Fri, 04 Jun 2021 17:41:49 +0800</pubDate></item><item><title>终于来了！150+肿瘤临床试验信息汇总，转给需要的人</title><link>https://mp.weixin.qq.com/s/pI1gzusbGb-E6418xZMLjQ</link><description></description><content:encoded><![CDATA[终于来了！150+肿瘤临床试验信息汇总，转给需要的人]]></content:encoded><pubDate>Fri, 04 Jun 2021 17:41:16 +0800</pubDate></item><item><title>【肝癌招募】 神州PD-1联合抗VEGF抗体对比索拉非尼招募晚期肝细胞癌患者</title><link>https://mp.weixin.qq.com/s/gZgGiUFa77PZHsqLVkyOMA</link><description></description><content:encoded><![CDATA[【肝癌招募】 神州PD-1联合抗VEGF抗体对比索拉非尼招募晚期肝细胞癌患者]]></content:encoded><pubDate>Wed, 02 Jun 2021 12:09:20 +0800</pubDate></item><item><title>【食管癌招募】神州细胞PD-1与EGFR抑制剂联合化疗招募晚期食管鳞癌患者</title><link>https://mp.weixin.qq.com/s/CNryTET962hA06UqwJA-sg</link><description></description><content:encoded><![CDATA[【食管癌招募】神州细胞PD-1与EGFR抑制剂联合化疗招募晚期食管鳞癌患者]]></content:encoded><pubDate>Wed, 02 Jun 2021 12:00:14 +0800</pubDate></item><item><title>免疫+靶向！神州细胞PD-1与EGFR抑制剂招募晚期结直肠癌患者</title><link>https://mp.weixin.qq.com/s/MXnD0ZIRV8h6Jd3xox93bg</link><description></description><content:encoded><![CDATA[免疫+靶向！神州细胞PD-1与EGFR抑制剂招募晚期结直肠癌患者]]></content:encoded><pubDate>Tue, 01 Jun 2021 17:49:47 +0800</pubDate></item></channel></rss>